CORT - Corcept Therapeutics Inc. Profit before interest, taxes and amortization

Brandmark of Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics (CORT) specializes in the therapy of endocrine pathologies, where success is based on the sales of its primary drug and patent victories. The company's absolute operating profit in monetary terms demonstrates current efficiency, with the latest value recorded as 114.09. Growth is supported by a monopoly in the treatment of Cushing's disease and investments in oncological molecules, while high margins are ensured by a unique intellectual property portfolio.

Corcept - CORT Operating profit EBITDA (period 11/23/2025 - 11/11/2026)

Summary analytical data breakdowns for Corcept Therapeutics Incorporated (CORT)

- current quotes and average value forecast:
Stock Quotes Corcept Therapeutics Corp|CORT - Analyst Consensus Forecast
- market capitalization statistics:
Market Value Corcept Therapeutics|CORT - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share Corcept Therapeutics|CORT - Book Capitalization|Market Capitalization to Book Value Ratio corcept.com|CORT - Company Total Assets
- company total debt and liquidity indicators:
Debt to Equity Corcept Therapeutics|CORT - Long-Term Debt to Equity|Current Liabilities to Capital Corcept Therapeutics Inc.|CORT - Company Debts|Debt to Book Capitalization Ratio Corcept Therapeutics|CORT - Company Long-Term Debts|Short-Term Debt Volume Corcept Therapeutics|Interim Coverage Ratio corcept.com
- financial results and valuation multiples details:
CORT - Company Net Income|Future Profit Corcept Therapeutics|CORT - P/E Multiple|Projected Price to Earnings corcept.com|CORT - Price/Earnings to Growth Ratio|Company Value to EBITDA Corcept Therapeutics|CORT - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Corcept Therapeutics|CORT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months corcept.com|CORT - Earnings growth in current year|Expected net earnings per share growth next year Corcept Therapeutics
Analysis of all company metrics:Corcept Therapeutics Corp (CORT)
Manufactured products of Corcept Therapeutics

This indicator tracks daily operating profit in fiat equivalent, excluding accounting lags to assess the business's actual dependence on market conditions. The current value of 114.09 on the GURU.Markets chart reflects the monetization efficiency of Corcept Therapeutics (CORT) patents in cortisol modulation, where the company's operating profit confirms the revenue stability derived from exclusive therapies for rare endocrine pathologies.

Who Corcept Therapeutics competes with

ASND - Operating profit before deduction of amortization|Madrigal Pharmaceuticals - Operating profit EBITDA|Profit before interest, taxes and amortization rhythmtx.com|AKRO (Akero) - Operating profit before deduction of amortization|MTSR: Company profit before taxes, interest and amortization|MLTX (MoonLake Pharma) - Operating profit EBITDA|Operating profit EBITDA Crinetics Corp|Operating profit EBITDA NAMS|Profit before payment of interest, taxes and amortization SLNO (soleno.life)|Profit before payment of interest, taxes and amortization Amicus Therapeutics, Inc. FOLD|89bio Inc (ETNB) - Profit before interest, taxes and amortization|AGIO - Profit before payment of interest, taxes and amortization|GPCR: Profit before payment of interest, taxes and amortization|MDXG: Operating profit EBITDA|RZLT - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Lexicon Pharmaceuticals, Inc.|MBX Biosciences, Inc. (MBX) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Altimmune Corp (ALT)|Operating profit before deduction of amortization Aardvark Pharma AARD|Operating profit EBITDA SGMT (Sagimet Biosciences)|BIOA - Operating profit before deduction of amortization|BMEA - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Quince Therapeutics|Fractyl (GUTS) - Profit before payment of interest, taxes and amortization|vTv Therapeutics - Income before deduction of interest, taxes and amortization|ATPC (Agape ATP Corp) - Operating profit EBITDA|Operating profit before deduction of amortization Pluri Inc (PLUR)|Operating profit EBITDA SYBX|LPCN - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Matinas BioPharma Holdings MTNB|SPRB (sprucebiosciences.com) - Profit before deduction of interest, taxes, depreciation and amortization|GLTO: Operating profit before deduction of amortization|carmellrx.com - Company profit before taxes, interest and amortization|LUMO (Lumos Pharma) - Operating profit before deduction of amortization|Organovo Holdings - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization RDUS